PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Weiss Ratings downgraded shares of PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 11th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Down 3.9%

Shares of NASDAQ PDSB opened at $0.77 on Friday. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. The firm has a market capitalization of $42.87 million, a price-to-earnings ratio of -1.20 and a beta of 1.46. The business has a 50-day moving average of $0.50 and a 200-day moving average of $0.79.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Sell-side analysts expect that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in PDS Biotechnology in the second quarter worth approximately $60,000. BlackRock Inc. bought a new position in PDS Biotechnology during the second quarter valued at approximately $535,000. Finally, Renaissance Technologies LLC raised its stake in shares of PDS Biotechnology by 25.0% during the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after acquiring an additional 44,100 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.